Evaluating Glycemic Control During Basalin or Lantus Administration in Adults With Controlled Type 2 Diabetes Mellitus Using Continuous Glucose Monitoring

AimThis study aims at evaluating glycemic control during Basalin or Lantus administration in adults with controlled type 2 diabetes mellitus using continuous glucose monitoring system (CGM).Methods47 patients with well-controlled T2DM using both Basalin and oral hypoglycemic drugs were recruited. CG...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Huiying Wang, Yunting Zhou, Xiaofang Zhai, Bo Ding, Ting Jing, Xiaofei Su, Huiqin Li, Jianhua Ma
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	insulin glargine continuous glucose monitoring system glycemic variability Basalin Lantus Diseases of the endocrine glands. Clinical endocrinology RC648-665
Acceso en línea:	https://doaj.org/article/d01c178a87c6443f8a1209034651154c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d01c178a87c6443f8a1209034651154c
record_format	dspace
spelling	oai:doaj.org-article:d01c178a87c6443f8a1209034651154c2021-12-01T19:45:58ZEvaluating Glycemic Control During Basalin or Lantus Administration in Adults With Controlled Type 2 Diabetes Mellitus Using Continuous Glucose Monitoring1664-239210.3389/fendo.2021.754820https://doaj.org/article/d01c178a87c6443f8a1209034651154c2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fendo.2021.754820/fullhttps://doaj.org/toc/1664-2392AimThis study aims at evaluating glycemic control during Basalin or Lantus administration in adults with controlled type 2 diabetes mellitus using continuous glucose monitoring system (CGM).Methods47 patients with well-controlled T2DM using both Basalin and oral hypoglycemic drugs were recruited. CGM were applied from day 1 to day 3 with the unchanged dose of Basalin and then removed from day 4. A washout was performed with Lantus at the same dose as Basalin from day 4 to day 10. Then patients were continued to install the CGM under Lantus administration from day 11 to day 13. Variables of CGM, such as the area under the curve (AUC) for both hyperglycemia and hypoglycemia, 24h mean blood glucose (24h MBG), 24h standard deviation of blood glucose (24h SDBG), 24h mean amplitude of glycemic excursion (24h MAGE), PT (percentage of time), and time in range (TIR), were calculated and compared between Basalin group and Lantus group.ResultsThe group of Lantus showed lower 24h MBG (p<0.01), 24h MAGE (p<0.05), and lower 24h SDBG (p<0.01) than the Basalin group. Lantus−treated patients had a lower PT and AUC when the cut-off point for blood glucose was 10 mmol/L (p<0.05) and 13.9 mmol/L (p<0.05), respectively. In this study, no patient developed symptomatic hypoglycemia, few hypoglycemia was observed and there was no difference of hypoglycemia between the two groups.ConclusionIn patients with well-controlled T2DM who were treated with insulin glargine, Lantus group showed lower MBG, GV, and lower PT (BG > 10.0 mmol/L, BG > 13.9 mmol/L) than Basalin group. In summary, for T2DM population with HbA1c ≤ 7%, Lantus may be a better choice compared with Basalin.Huiying WangYunting ZhouXiaofang ZhaiBo DingTing JingXiaofei SuHuiqin LiJianhua MaFrontiers Media S.A.articleinsulin glarginecontinuous glucose monitoring systemglycemic variabilityBasalinLantusDiseases of the endocrine glands. Clinical endocrinologyRC648-665ENFrontiers in Endocrinology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	insulin glargine continuous glucose monitoring system glycemic variability Basalin Lantus Diseases of the endocrine glands. Clinical endocrinology RC648-665
spellingShingle	insulin glargine continuous glucose monitoring system glycemic variability Basalin Lantus Diseases of the endocrine glands. Clinical endocrinology RC648-665 Huiying Wang Yunting Zhou Xiaofang Zhai Bo Ding Ting Jing Xiaofei Su Huiqin Li Jianhua Ma Evaluating Glycemic Control During Basalin or Lantus Administration in Adults With Controlled Type 2 Diabetes Mellitus Using Continuous Glucose Monitoring
description	AimThis study aims at evaluating glycemic control during Basalin or Lantus administration in adults with controlled type 2 diabetes mellitus using continuous glucose monitoring system (CGM).Methods47 patients with well-controlled T2DM using both Basalin and oral hypoglycemic drugs were recruited. CGM were applied from day 1 to day 3 with the unchanged dose of Basalin and then removed from day 4. A washout was performed with Lantus at the same dose as Basalin from day 4 to day 10. Then patients were continued to install the CGM under Lantus administration from day 11 to day 13. Variables of CGM, such as the area under the curve (AUC) for both hyperglycemia and hypoglycemia, 24h mean blood glucose (24h MBG), 24h standard deviation of blood glucose (24h SDBG), 24h mean amplitude of glycemic excursion (24h MAGE), PT (percentage of time), and time in range (TIR), were calculated and compared between Basalin group and Lantus group.ResultsThe group of Lantus showed lower 24h MBG (p<0.01), 24h MAGE (p<0.05), and lower 24h SDBG (p<0.01) than the Basalin group. Lantus−treated patients had a lower PT and AUC when the cut-off point for blood glucose was 10 mmol/L (p<0.05) and 13.9 mmol/L (p<0.05), respectively. In this study, no patient developed symptomatic hypoglycemia, few hypoglycemia was observed and there was no difference of hypoglycemia between the two groups.ConclusionIn patients with well-controlled T2DM who were treated with insulin glargine, Lantus group showed lower MBG, GV, and lower PT (BG > 10.0 mmol/L, BG > 13.9 mmol/L) than Basalin group. In summary, for T2DM population with HbA1c ≤ 7%, Lantus may be a better choice compared with Basalin.
format	article
author	Huiying Wang Yunting Zhou Xiaofang Zhai Bo Ding Ting Jing Xiaofei Su Huiqin Li Jianhua Ma
author_facet	Huiying Wang Yunting Zhou Xiaofang Zhai Bo Ding Ting Jing Xiaofei Su Huiqin Li Jianhua Ma
author_sort	Huiying Wang
title	Evaluating Glycemic Control During Basalin or Lantus Administration in Adults With Controlled Type 2 Diabetes Mellitus Using Continuous Glucose Monitoring
title_short	Evaluating Glycemic Control During Basalin or Lantus Administration in Adults With Controlled Type 2 Diabetes Mellitus Using Continuous Glucose Monitoring
title_full	Evaluating Glycemic Control During Basalin or Lantus Administration in Adults With Controlled Type 2 Diabetes Mellitus Using Continuous Glucose Monitoring
title_fullStr	Evaluating Glycemic Control During Basalin or Lantus Administration in Adults With Controlled Type 2 Diabetes Mellitus Using Continuous Glucose Monitoring
title_full_unstemmed	Evaluating Glycemic Control During Basalin or Lantus Administration in Adults With Controlled Type 2 Diabetes Mellitus Using Continuous Glucose Monitoring
title_sort	evaluating glycemic control during basalin or lantus administration in adults with controlled type 2 diabetes mellitus using continuous glucose monitoring
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/d01c178a87c6443f8a1209034651154c
work_keys_str_mv	AT huiyingwang evaluatingglycemiccontrolduringbasalinorlantusadministrationinadultswithcontrolledtype2diabetesmellitususingcontinuousglucosemonitoring AT yuntingzhou evaluatingglycemiccontrolduringbasalinorlantusadministrationinadultswithcontrolledtype2diabetesmellitususingcontinuousglucosemonitoring AT xiaofangzhai evaluatingglycemiccontrolduringbasalinorlantusadministrationinadultswithcontrolledtype2diabetesmellitususingcontinuousglucosemonitoring AT boding evaluatingglycemiccontrolduringbasalinorlantusadministrationinadultswithcontrolledtype2diabetesmellitususingcontinuousglucosemonitoring AT tingjing evaluatingglycemiccontrolduringbasalinorlantusadministrationinadultswithcontrolledtype2diabetesmellitususingcontinuousglucosemonitoring AT xiaofeisu evaluatingglycemiccontrolduringbasalinorlantusadministrationinadultswithcontrolledtype2diabetesmellitususingcontinuousglucosemonitoring AT huiqinli evaluatingglycemiccontrolduringbasalinorlantusadministrationinadultswithcontrolledtype2diabetesmellitususingcontinuousglucosemonitoring AT jianhuama evaluatingglycemiccontrolduringbasalinorlantusadministrationinadultswithcontrolledtype2diabetesmellitususingcontinuousglucosemonitoring
_version_	1718404600660230144

Evaluating Glycemic Control During Basalin or Lantus Administration in Adults With Controlled Type 2 Diabetes Mellitus Using Continuous Glucose Monitoring

Ejemplares similares